Humalog Mix 75 / 25

See also: Generic Humalog Mix 50/50, Generic Humalog Mix 50/50 KwikPen, Generic Humalog Mix 50/50 Pen, Generic Humalog Mix 75/25 KwikPen, Generic Humalog Mix 75/25 Pen

Humalog Mix 75/25 is a brand name of insulin lispro/insulin lispro protamine, approved by the FDA in the following formulation(s):

HUMALOG MIX 75/25 (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)

• 
  Manufacturer: LILLY
  
  Approval date: December 22, 1999
  
  Strength(s): 75 UNITS/ML;25 UNITS/ML ^[RLD]

Has a generic version of Humalog Mix 75/25 been approved?

No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Monomeric insulin analog formulations
  Patent 5,461,031
  Issued: October 24, 1995
  Inventor(s): De Felippis; Michael R.
  Assignee(s): Eli Lilly and Company
  The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
  
  Patent expiration dates:
  
  
  • June 16, 2014
    
  
  



• 
  Insulin analog formulations
  Patent 5,474,978
  Issued: December 12, 1995
  Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
  Assignee(s): Eli Lilly and Company
  The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
  
  Patent expiration dates:
  
  
  • June 16, 2014
    
  
  



• 
  Insulin analogs modified at position 29 of the B chain
  Patent 5,514,646
  Issued: May 7, 1996
  Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
  Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
  
  Patent expiration dates:
  
  
  • May 7, 2013
    
  
  



• 
  Monomeric insulin analog formulations
  Patent 5,747,642
  Issued: May 5, 1998
  Inventor(s): De Felippis; Michael R.
  Assignee(s): Eli Lilly and Company
  The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
  
  Patent expiration dates:
  
  
  • June 16, 2014
    
  
  

See also...

• HumaLog Mix 75/25 Vials Consumer Information (Wolters Kluwer)
• Humalog Mix 75/25 Pens Consumer Information (Wolters Kluwer)
• Humalog Mix 75/25 Consumer Information (Cerner Multum)
• Humalog Mix 75/25 Advanced Consumer Information (Micromedex)
• Humalog Mix Consumer Information (Drugs.com)
• Insulin Lispro Protamine/Insulin Lispro Pens Consumer Information (Wolters Kluwer)
• Insulin Lispro Protamine/Insulin Lispro Vials Consumer Information (Wolters Kluwer)
• Insulin lispro and insulin lispro protamine Consumer Information (Cerner Multum)
• Insulin lispro protamine and insulin lispro Subcutaneous Advanced Consumer Information (Micromedex)